JP2020511931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511931A5 JP2020511931A5 JP2018565824A JP2018565824A JP2020511931A5 JP 2020511931 A5 JP2020511931 A5 JP 2020511931A5 JP 2018565824 A JP2018565824 A JP 2018565824A JP 2018565824 A JP2018565824 A JP 2018565824A JP 2020511931 A5 JP2020511931 A5 JP 2020511931A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- recombinase
- double
- genome
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 230000005782 double-strand break Effects 0.000 claims 16
- 108010091086 Recombinases Proteins 0.000 claims 15
- 102000018120 Recombinases Human genes 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 14
- 239000013598 vector Substances 0.000 claims 12
- 101710163270 Nuclease Proteins 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 230000014509 gene expression Effects 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 8
- 102000004190 Enzymes Human genes 0.000 claims 7
- 108090000790 Enzymes Proteins 0.000 claims 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 6
- 108091033409 CRISPR Proteins 0.000 claims 4
- 108020005004 Guide RNA Proteins 0.000 claims 4
- 208000009869 Neu-Laxova syndrome Diseases 0.000 claims 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 4
- 230000006801 homologous recombination Effects 0.000 claims 4
- 238000002744 homologous recombination Methods 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 3
- 238000010362 genome editing Methods 0.000 claims 3
- 108020004705 Codon Proteins 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 108010068097 Rad51 Recombinase Proteins 0.000 claims 2
- 102000002490 Rad51 Recombinase Human genes 0.000 claims 2
- 102000001218 Rec A Recombinases Human genes 0.000 claims 2
- 108010055016 Rec A Recombinases Proteins 0.000 claims 2
- 241000700584 Simplexvirus Species 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- -1 meganuclease Proteins 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 230000004186 co-expression Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662350941P | 2016-06-16 | 2016-06-16 | |
| US62/350,941 | 2016-06-16 | ||
| PCT/IB2017/000967 WO2018229521A1 (en) | 2016-06-16 | 2017-06-16 | Improved gene editing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020511931A JP2020511931A (ja) | 2020-04-23 |
| JP2020511931A5 true JP2020511931A5 (enExample) | 2020-07-30 |
Family
ID=65019181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565824A Abandoned JP2020511931A (ja) | 2016-06-16 | 2017-06-16 | 改良された遺伝子編集 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11708588B2 (enExample) |
| EP (1) | EP3472329A1 (enExample) |
| JP (1) | JP2020511931A (enExample) |
| CN (1) | CN109790551A (enExample) |
| CA (1) | CA3028074A1 (enExample) |
| CL (1) | CL2018003649A1 (enExample) |
| WO (1) | WO2018229521A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3976783A1 (en) * | 2019-05-29 | 2022-04-06 | Monsanto Technology LLC | Directed genome engineering using enhanced targeted editing technologies |
| CN112979821B (zh) * | 2019-12-18 | 2022-02-08 | 华东师范大学 | 一种提高基因编辑效率的融合蛋白及其应用 |
| CN111518220A (zh) * | 2020-05-14 | 2020-08-11 | 重庆英茂盛业生物科技有限公司 | 一种融合蛋白及其设计方法 |
| CN111909961B (zh) * | 2020-08-21 | 2022-04-19 | 华侨大学 | 一种CRISPR/Cas介导的ATL细胞基因编辑载体及其应用 |
| WO2022095929A1 (en) * | 2020-11-06 | 2022-05-12 | The University Of Hong Kong | Transferable type i-f crispr-cas genome editing system |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| ATE141646T1 (de) | 1986-04-09 | 1996-09-15 | Genzyme Corp | Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7868149B2 (en) | 1999-07-20 | 2011-01-11 | Monsanto Technology Llc | Plant genome sequence and uses thereof |
| US6603061B1 (en) | 1999-07-29 | 2003-08-05 | Monsanto Company | Agrobacterium-mediated plant transformation method |
| AU2002238376B2 (en) | 2001-01-10 | 2007-05-10 | Lonza Cologne Gmbh | Modular transfection systems based on nucleoprotein filaments |
| US20090100536A1 (en) | 2001-12-04 | 2009-04-16 | Monsanto Company | Transgenic plants with enhanced agronomic traits |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| BR112013021785A8 (pt) * | 2011-02-25 | 2018-07-03 | Recombinetics Inc | animais geneticamente modificados e métodos para fazer os mesmos |
| EP3257952B1 (en) * | 2012-09-11 | 2020-02-12 | Life Technologies Corporation | Nucleic acid amplification |
| AP2015008495A0 (en) * | 2012-10-30 | 2015-05-31 | Ct For Aquaculture Technologies Inc | Control of sexual maturation in animals |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| JP6665088B2 (ja) | 2013-06-17 | 2020-03-13 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物 |
| BR112016013547A2 (pt) | 2013-12-12 | 2017-10-03 | Broad Inst Inc | Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos |
| CN104946621A (zh) | 2014-03-28 | 2015-09-30 | 中国科学院上海生命科学研究院 | 基因敲入组合物及其使用方法和应用 |
| DK3180426T3 (da) * | 2014-08-17 | 2020-03-30 | Broad Inst Inc | Genomredigering ved anvendelse af cas9-nickaser |
| IL287561B2 (en) * | 2014-10-01 | 2024-03-01 | Massachusetts Gen Hospital | Methods for increasing efficiency of nuclease-induced homology-directed repair |
| WO2016073990A2 (en) * | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| EP3274453B1 (en) | 2015-03-26 | 2021-01-27 | Editas Medicine, Inc. | Crispr/cas-mediated gene conversion |
| US9988637B2 (en) * | 2015-10-26 | 2018-06-05 | National Tsing Hua Univeristy | Cas9 plasmid, genome editing system and method of Escherichia coli |
-
2017
- 2017-06-16 CN CN201780050339.4A patent/CN109790551A/zh active Pending
- 2017-06-16 JP JP2018565824A patent/JP2020511931A/ja not_active Abandoned
- 2017-06-16 US US16/310,664 patent/US11708588B2/en active Active
- 2017-06-16 CA CA3028074A patent/CA3028074A1/en active Pending
- 2017-06-16 EP EP17758941.3A patent/EP3472329A1/en not_active Withdrawn
- 2017-06-16 WO PCT/IB2017/000967 patent/WO2018229521A1/en not_active Ceased
-
2018
- 2018-12-17 CL CL2018003649A patent/CL2018003649A1/es unknown
-
2023
- 2023-06-30 US US18/345,653 patent/US20230416788A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7698828B2 (ja) | Ｒｎａを編集する方法および組成物 | |
| Broeders et al. | Sharpening the molecular scissors: advances in gene-editing technology | |
| Akram et al. | An insight into modern targeted genome-editing technologies with a special focus on CRISPR/Cas9 and its applications | |
| CN103224947B (zh) | 一种基因打靶系统 | |
| KR101785847B1 (ko) | 선형 이중가닥 ＤＮＡ를 활용한 ＣＲＩＳＰＲ／Ｃａｓ９ 시스템을 이용한 표적 유전체 교정 | |
| JP2016500262A5 (enExample) | ||
| US10858662B2 (en) | Genome editing with split Cas9 expressed from two vectors | |
| JP2016165307A5 (enExample) | ||
| US20190119678A1 (en) | Means and methods for inactivating therapeutic dna in a cell | |
| JP2019115348A5 (enExample) | ||
| Cao et al. | The multiplexed CRISPR targeting platforms | |
| Yuan et al. | A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9 | |
| AU2018222092A1 (en) | Genome editing system and method | |
| JP2015510778A5 (enExample) | ||
| CN107794272A (zh) | 一种高特异性的crispr基因组编辑体系 | |
| Jo et al. | CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods | |
| CN104805078A (zh) | 用于高效基因组编辑的rna分子的设计、合成及其应用 | |
| WO2017215648A1 (zh) | 基因敲除方法 | |
| EP3733842A1 (en) | System and method for genome editing | |
| JP2020519304A5 (enExample) | ||
| JP2016501531A5 (enExample) | ||
| JP2016501532A5 (enExample) | ||
| CN107151677B (zh) | 基于CRISPR/Cas9多基因敲除低转染效率细胞系的方法 | |
| CN102703424B (zh) | 一种重组工程介导的大肠杆菌基因组点突变的方法 | |
| CN104560995B (zh) | 一对特异识别猪H11位点的sgRNA及其编码DNA和应用 |